Jubilant Pharmova Ltd Share Price

Q: What is the share price of Jubilant Pharmova Ltd today?

Jubilant Pharmova Ltd share price as on 22 Jan 2025 is ₹938.05

Pharmaceuticals - Indian - Bulk Drugs

NSE: JUBLPHARMA Small Cap ISIN: INE700A01033

As on 22 January 2025 at 15:58 IST

₹938.05

-5.80

(-0.61%)

Sell Buy

About Jubilant Pharmova Ltd

Jubilant Pharmova Ltd is a global integrated pharmaceutical and life sciences company. Founded in 1978, it has transformed from a small chemical manufacturer to a global pharmaceutical player under the Bhartia family's leadership. The company is headquartered in Uttar Pradesh, India. It specializes in allergy therapy products, sterile injectables, and Active Pharmaceutical Ingredients (APIs). Through its subsidiary Jubilant Biosys, it provides contract research and development services. Operating in the pharmaceutical and life sciences sector, the company has established itself as a significant player in specific segments like radiopharmaceuticals in North America. Read More...

Over 1 Month

-11.35%

Over 6 Months

30.31%

Over 1 Year

76.34%

Over 3 Years

71.06%

Jubilant Pharmova Ltd Summary

Close ₹ 938.05

Open ₹ 944

High ₹ 948.75

Low ₹ 925

Volume 99,647

Net Turnover (in ₹) ₹ 19,63,73,670.45

52Wk High ₹ 1,309.90

52Wk Low ₹ 532.15

52Wk High / Low

532.15

1,309.90

Jubilant Pharmova Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 15,035.53

EPS (TTM) 2.61

Book Value (BV) 144.30

Div. Yield 0.53 %

P/E (TTM) 493.61

Price/Book Value 6.53

Delivery % 33.80 %

Face Value 1

Key Ratios

PE Ratio 285.68

PB Ratio 3.81

EV to Sales 11.98

PEG Ratio -7.80

ROA 1.14

ROE 1.32

Debt-Equity 0.15

Net Profit Margin 4.03

Operating Profit Margin 15.28

Jubilant Pharmova Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	6,771.60	6,320	6,141.45	6,116.17	6,013.20
Total Expenses	6,456.30	6,247.70	5,501.02	5,235.12	4,967.39
Profit Before Tax	170.50	27.80	630.45	871.08	1,012.88
Profit After Tax	72.70	-64.90	413.02	573.86	677.77
Operating Profit after Depreciation	587.60	260.50	785.92	1,065.15	1,245.52

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	5,942	5,971.50	5,668.35	5,227.96	6,844.74
Total Non Current Assets	7,672.40	7,394.30	6,481.68	5,965.61	7,483.30
Total Current Assets	3,876.10	3,762.40	3,509.19	2,952.50	5,038.35
TOTAL ASSETS	11,548.50	11,156.70	9,990.87	8,918.11	12,521.65
Total Shareholder's Fund	5,433.90	5,399.30	5,318.56	4,741.49	5,603.88

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	971.30	660.70	837.54	1,784.27	1,542.94
Net Cash used in Investing Activities	-596.30	-473.90	-323.08	-726.76	-267.15
Net Cash used in Financing Activities	-432.50	-156.70	-32.60	-1,709.39	-1,050.37

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	888.10	948	213.62	2,757.38	3,313.13
Total Expenses	846.40	868.70	131.37	2,484.21	3,012.59
Profit Before Tax	41.70	79.30	82.25	273.17	298.84
Profit After Tax	31.60	49.90	78.50	214.47	321.14
Operating Profit after Depreciation	71.60	97.80	112.83	374.97	436.74

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	711.30	687.40	123.54	127.08	1,865.40
Total Non Current Assets	2,451.30	2,429.60	1,781.57	1,778.35	3,711.26
Total Current Assets	540.60	578.80	47.90	66.25	1,722.13
TOTAL ASSETS	2,991.90	3,008.40	1,829.47	1,844.60	5,433.39
Total Shareholder's Fund	2,374.50	2,414.50	1,281.82	1,282.44	2,607.30

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	143.20	-65.10	-3.55	608.38	316.76
Net Cash used in Investing Activities	-40.30	31.10	93.10	177.96	-197.71
Net Cash used in Financing Activities	-77.80	22.50	-107.37	-781.65	-41.05

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	1,752.30	1,731.70	1,758.60	1,677.10	1,680.30
Total Expenses	1,463	1,480.20	1,487.20	1,459.10	1,438.50
Profit Before Tax	144.40	499.70	-53.70	101	98
Profit After Tax	102.50	481.80	-61.80	66.40	62.10
Operating Profit after Depreciation	311	265.50	289.20	266.90	260.70

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	165.70	166.70	205.80	175.20	186.30
Total Expenses	171.80	165.50	193.60	175.90	185.50
Profit Before Tax	16.60	-11.20	41.50	-2.30	0.20
Profit After Tax	10.50	-10.20	32.50	-2.40	-0.40
Operating Profit after Depreciation	37.70	20.70	62.30	18.30	19.20

Jubilant Pharmova Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 922.67

S2 901.48

S3 862.97

Pivot 961.18

R1 982.37

R2 1,020.88

R3 1,042.07

Moving Average

20 SMA 1,019.74

50 SMA 1,099.62

100 SMA 1,114.11

200 SMA 926.70

Jubilant Pharmova Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Jubilant Pharmova Ltd

₹5/Share

Announcement Date 02 Aug 2024

Record Date 02 Aug 2024

Div Yield 500%

Jubilant Pharmova Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Jubilant Pharmova Ltd	₹942.80	₹15,018.80
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

Jubilant Pharmova Ltd News

Jubilant Pharmova's Salisbury-based facility gets five observations from US FDA

Jubilant Pharmova said that the solid oral formulations facility of its subsidiary Jubilant Cadista Pharmaceuticals Inc., which is located at Salisbury, Maryland, USA, has received five observations from the US FDA.

17 Jan 2025, 09:34 am

Jubilant Cadista's Salisbury unit undergoes USFDA inspection

17 Jan 2025, 09:14 am

Volumes spurt at Jubilant Pharmova Ltd counter

Jubilant Pharmova Ltd notched up volume of 5.34 lakh shares by 10:46 IST on BSE, a 29 fold spurt over two-week average daily volume of 18403 shares

16 Dec 2024, 11:00 am

Jubilant Pharmova to conduct board meeting

On 25 October 2024

18 Oct 2024, 10:41 am

Jubilant Pharmova gains as Washington unit gets VAI classification from USFDA

Jubilant Pharmova advanced 1.60% to Rs 1,033.55 after its subsidiary, Jubilant HollisterStier LLC's (JHS) manufacturing facility located at Spokane, Washington (USA) received classification of 'Voluntary Action Indicated' from USFDA.

11 Sep 2024, 10:52 am

Jubilant Pharmova Ltd Stock Analysis

Annual revenue for Jubilant Pharmova Ltd decreased by 6.32% to ₹888.10 crore in FY 2024 from ₹948 crore in FY 2023.
Annual Net Profit for Jubilant Pharmova Ltd decreased by 36.67% to ₹31.60 crore in FY 2024 from ₹49.90 crore in FY 2023.
Promoter Shareholding in Jubilant Pharmova Ltd remains unchanged by 0.00% in the most recent quarter, from 50.68% in June 2024 to 50.68% in September 2024.
Jubilant Pharmova Ltd delivered a 1-year return of 76.34% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Jubilant Pharmova Ltd share price moved down by 0.61% from its previous close of INR ₹943.85. The latest Jubilant Pharmova Ltd share price is INR ₹938.05.
Jubilant Pharmova Ltd share price today has been at a low of 925 and a high of 948.75. Over the past 52 weeks, the Jubilant Pharmova Ltd share price has seen a low of 532.15 and a high of 1,309.90.

About Jubilant Pharmova Ltd

Jubilant Pharmova Ltd. (formerly Jubilant Life Sciences) is a global integrated pharmaceutical and life sciences company. The company operates in the pharmaceutical and life sciences sectors. It focuses on pharmaceutical manufacturing, contract research, and drug discovery services.

Established in 1978, the company has over many decades of experience in the pharmaceutical industry. The company's headquarters is located in Uttar Pradesh, India.

The company is promoted by the Bhartia family. Shyam S. Bhartia serves as Chairman, and Hari S. Bhartia is Co-Chairman and Managing Director. The Bhartia family has been instrumental in transforming the company from a small chemical manufacturer to a global pharmaceutical player.
The other crucial managerial promoters of the company include:

Priyavrat Bhartia
Arjun Shanker Bhartia
Arvind Chokhany

Jubilant Pharmova's main products include Radiopharmaceuticals and Allergy Therapy Products. It also offers Contract Manufacturing of Sterile Injectables and Active Pharmaceutical Ingredients (APIs). They also provide Contract Research and Development Services through their subsidiary Jubilant Biosys.

Jubilant Pharmova is a significant player in the pharmaceutical sector. However, it is not the #1 company in terms of market capitalization or market share in India's pharmaceutical sector. The company has established itself as one of the leading players in specific segments like radiopharmaceuticals in North America. The promoter shareholding in the company stands at 50.68%. This indicates strong promoter confidence in the business.

The company's registered office is located at Bhartiagram, Gajraula, Amroha Dist., Uttar Pradesh - 244223, India. KFin Technologies Limited serves as the Registrar and Transfer Agent. The company's board comprises a mix of executive and independent directors, ensuring proper corporate governance.

Influence of the Company

Jubilant Pharmova Ltd. stands as a testament to India's growing prominence in the global pharmaceutical landscape. Since its establishment in 1978, the company has undergone a remarkable transformation from a modest chemical manufacturer to a multinational pharmaceutical and life sciences organization. The evolution was steered by the visionary leadership of the Bhartia family. This represents corporate success and India's capability to compete and excel in the global pharmaceutical arena. The company's journey reflects the dynamic nature of the pharmaceutical industry and demonstrates how strategic leadership can drive sustainable growth and innovation.

The company's influence is reflected in its organizational structure and leadership approach. Under the guidance of Chairman Shyam S. Bhartia, Jubilant Pharmova has cultivated a culture of innovation and excellence. The substantial promoter shareholding has proven to be a crucial factor in maintaining stable leadership and enabling long-term strategic planning. This strong promoter backing has allowed the company to make bold decisions and investments in emerging pharmaceutical segments. This contributes to its sustained growth and influence in the industry.

In the sector of specialized pharmaceuticals, Jubilant Pharmova has carved out a distinctive niche. Their radiopharmaceutical division has become particularly influential in North America. At this place, they have established themselves as a key player in nuclear medicine. This achievement is significant as it demonstrates an Indian company's ability to succeed in highly regulated and technologically advanced markets. Their expertise in allergy therapy products and sterile injectables manufacturing has made them a preferred partner for global pharmaceutical companies. This further enhances India's reputation in the global pharmaceutical supply chain.

The company's Active Pharmaceutical Ingredients (APIs) business has played a crucial role in strengthening India's position as the 'pharmacy of the world.' By ensuring a reliable supply of high-quality APIs, Jubilant Pharmova has contributed to the security and stability of global pharmaceutical supply chains. In this factor, it gained particular significance during global health crises. This has helped establish India's credibility as a dependable source of pharmaceutical products and ingredients.

Through their subsidiary Jubilant Biosys, the company has made substantial contributions to pharmaceutical research and development. Their contract research services have been instrumental in accelerating drug discovery. Also, their research helped various pharmaceutical companies improve their development processes. This has not only generated revenue but has also positioned India as a hub for pharmaceutical research and development, attracting international collaboration and investment.

The company's influence extends to corporate governance and management practices. Their professional management team has set high standards for corporate governance in the Indian pharmaceutical sector. This has helped build trust among international partners and investors, facilitating global expansion and partnerships.

The influence of Jubilant Pharmova is also evident in its commitment to sustainability and social responsibility. Their business practices have demonstrated that pharmaceutical companies can balance profitability with environmental and social considerations. This sets an example for other companies in the sector.

The company's journey from a chemical manufacturer to a global pharmaceutical player serves as an inspiration for emerging pharmaceutical companies, particularly in developing nations. Jubilant Pharmova continues to shape the pharmaceutical industry's future. This is done through its diverse operations, strong leadership, commitment to innovation, and adherence to high standards of corporate governance. The company's success story contributes to India's pharmaceutical prowess. Also, this demonstrates how pharmaceutical companies can evolve and adapt to meet changing global healthcare needs while maintaining ethical business practices. As the pharmaceutical industry continues to evolve, Jubilant Pharmova's influence is likely to grow. This further solidifies its position as a respected player in the global pharmaceutical and life sciences sector.